Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Computer-Aided Drug Design of Small Molecule Inhibitors of the ERCC1-XPF Protein-Protein Interaction.

Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA.

Chem Biol Drug Des. 2019 Dec 31. doi: 10.1111/cbdd.13660. [Epub ahead of print]

PMID:
31891209
3.

Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.

McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW.

DNA Repair (Amst). 2015 Jul;31:19-28. doi: 10.1016/j.dnarep.2015.04.002. Epub 2015 Apr 22.

PMID:
25956741
4.

Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.

Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.

Nutrients. 2018 Nov 3;10(11). pii: E1644. doi: 10.3390/nu10111644.

5.

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.

Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072.

6.

Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.

Su Y, Orelli B, Madireddy A, Niedernhofer LJ, Schärer OD.

J Biol Chem. 2012 Jun 22;287(26):21846-55. doi: 10.1074/jbc.M111.337899. Epub 2012 Apr 30.

7.

Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.

Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Weilbeer C, Mani RS, Barakat KH, Tuszynski JA, Weinfeld M, West FG.

J Med Chem. 2019 Sep 12;62(17):7684-7696. doi: 10.1021/acs.jmedchem.9b00326. Epub 2019 Aug 22.

PMID:
31369707
8.

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.

DNA Repair (Amst). 2010 Jul 1;9(7):745-53. doi: 10.1016/j.dnarep.2010.03.010. Epub 2010 Apr 24.

9.

Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52.

Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE.

J Biol Chem. 2004 Apr 2;279(14):13634-9. Epub 2004 Jan 20.

10.

Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.

Kirschner K, Melton DW.

Anticancer Res. 2010 Sep;30(9):3223-32. Review.

PMID:
20944091
11.

DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.

McNeil EM, Melton DW.

Nucleic Acids Res. 2012 Nov 1;40(20):9990-10004. doi: 10.1093/nar/gks818. Epub 2012 Aug 31. Review.

12.

Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.

Yang L, Ritchie AM, Melton DW.

Oncotarget. 2017 Jul 21;8(33):55246-55264. doi: 10.18632/oncotarget.19422. eCollection 2017 Aug 15.

13.

The Cerebro-oculo-facio-skeletal Syndrome Point Mutation F231L in the ERCC1 DNA Repair Protein Causes Dissociation of the ERCC1-XPF Complex.

Faridounnia M, Wienk H, Kovačič L, Folkers GE, Jaspers NG, Kaptein R, Hoeijmakers JH, Boelens R.

J Biol Chem. 2015 Aug 14;290(33):20541-55. doi: 10.1074/jbc.M114.635169. Epub 2015 Jun 17.

14.

DCAF7 is required for maintaining the cellular levels of ERCC1-XPF and nucleotide excision repair.

Kawara H, Akahori R, Wakasugi M, Sancar A, Matsunaga T.

Biochem Biophys Res Commun. 2019 Oct 29;519(1):204-210. doi: 10.1016/j.bbrc.2019.08.147. Epub 2019 Sep 4.

PMID:
31493872
15.

Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.

Ahmad A, Enzlin JH, Bhagwat NR, Wijgers N, Raams A, Appledoorn E, Theil AF, J Hoeijmakers JH, Vermeulen W, J Jaspers NG, Schärer OD, Niedernhofer LJ.

PLoS Genet. 2010 Mar 5;6(3):e1000871. doi: 10.1371/journal.pgen.1000871.

16.

ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.

Sabatella M, Pines A, Slyskova J, Vermeulen W, Lans H.

Cell Mol Life Sci. 2019 Aug 7. doi: 10.1007/s00018-019-03264-5. [Epub ahead of print]

PMID:
31392348
17.

New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.

Gentile F, Tuszynski JA, Barakat KH.

J Mol Graph Model. 2016 Apr;65:71-82. doi: 10.1016/j.jmgm.2016.02.010. Epub 2016 Feb 26.

PMID:
26939044
18.

Function and Interactions of ERCC1-XPF in DNA Damage Response.

Faridounnia M, Folkers GE, Boelens R.

Molecules. 2018 Dec 5;23(12). pii: E3205. doi: 10.3390/molecules23123205. Review.

19.

Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.

Priya Doss CG, Nagasundaram N.

Appl Biochem Biotechnol. 2014 Feb;172(3):1265-81. doi: 10.1007/s12010-013-0592-5. Epub 2013 Oct 26.

PMID:
24158589
20.

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.

Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C.

Mol Pharmacol. 2013 Jul;84(1):12-24. doi: 10.1124/mol.112.082347. Epub 2013 Apr 11.

PMID:
23580445

Supplemental Content

Support Center